Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now later-stage tilt small index

Cystic Fibrosis Pulmonary Exacerbation: later-stage trial registry

2 of 2 indexed Cystic Fibrosis Pulmonary Exacerbation trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #7,188 of 28,707 conditions by registered trial count.

2 US clinical trials · 2 currently recruiting · #7,188 of 28,707 conditions by registered trial count

Cystic Fibrosis Pulmonary Exacerbation: 2 US clinical trials tracked, 2 recruiting.

Cystic Fibrosis Pulmonary Exacerbation is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Chris Goss, running 1 of these trials.

Enrollment posture brief

Registry condition cystic-fibrosis-pulmonary-exacerbation

OPEN 2 | RECR 100% | LATE 1 | EARLY 0 | RANK #7188 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Cystic Fibrosis Pulmonar (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Cystic Fibrosis Pulmonary Exacerbation

Cystic Fibrosis Pulmonary Exacerbation lists 2 open slots (100% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Cystic Fibrosis Pulmonary Exacerbation on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Cystic Fibrosis Pulmonary Exacerbation is recruiting above its size-band peers.

    2 of 2 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 41

Phase Distribution

PhaseTrial count
Phase 4 1

Top Sponsors

Named interventions

Most-linked intervention names on Cystic Fibrosis Pulmonary Exacerbation records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Aminoglycoside Drug
1 trials
Beta-lactam antibiotic Drug
1 trials

US sites by state

Facility locations filed on Cystic Fibrosis Pulmonary Exacerbation trials. A trial with sites in several states counts in each.

Indiana 1 trials
Illinois 1 trials
Idaho 1 trials
Iowa 1 trials
Georgia 1 trials
Florida 1 trials
Colorado 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Cystic Fibrosis Pulmonary Exacerbation page

2 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 2 Cystic Fibrosis Pulmonary Exacerbation trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Chris Goss sponsors the most Cystic Fibrosis Pulmonary Exacerbation trials on record, review their full trial history before evaluating a specific study. See Chris Goss's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cystic Fibrosis Pulmonary Exacerbation condition card totals 2 registered trials; most-linked intervention Aminoglycoside; top US site state Indiana. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.